



British Pharmacopoeia

British Pharmacopoeia Commission Secretariat

MHRA, 10 South Colonnade
Canary Wharf, London
E14 4PU, United Kingdom
pharmacopoeia.com

Date: 20 Dec 2024

TO WHOM IT MAY CONCERN

FLUCLOXACILLIN ORAL SOLUTION BP 2025

RELATED SUBSTANCES LIMITS

It has come to our attention that there are discrepancies between the limits stated for the Related Substances test in the BP monograph and those in the registered specifications. Manufacturers of Flucloxacillin Oral Solution should comply with their registered specification limits for product release until the monograph is updated.

Please accept this as a notice of intent to amend the monograph on behalf of the British Pharmacopoeia Commission. The revised monograph will be published in a future edition of the British Pharmacopoeia - the current target publication is the BP 2026, which will come into force on 1st January 2026.

If you have any questions concerning this letter, please do not hesitate to contact the British Pharmacopoeia Secretariat (BPCOM@mhra.gov.uk)

Yours faithfully,

MR STEVE HOARE

Secretary & Scientific Director

Email: BPCOM@mhra.gov.uk